Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-05-17
2011-05-17
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S322000, C514S397000, C514S383000, C514S381000
Reexamination Certificate
active
07943650
ABSTRACT:
Disclosed in certain embodiments is a method of treating and/or mitigating prostate cancer, ovarian cancer, melanoma, colorectal cancer, breast cancer or lung cancer, comprising administering to an individual in need thereof a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula (I):whereT is optionally substituted phenyl;n is 1 to 6:C represents optionally substituted carbon; andD is imidazolyl;or a pharmaceutically acceptable salt or ester of said compound.
REFERENCES:
patent: 2058068 (1992-06-01), None
patent: WO 2008/124132 (2008-04-01), None
Sausville et al. (Cancer Research, 2006, vol. 66, pp. 3351-3354).
Johnson et al. (British J. of Cancer, 2001, 84(10):1424-1431).
Lens (Br. J. Nurs., 2008, vol. 17, No. 5, pp. 300-305).
Divers et al. (Cutis. 2004, vol. 73, No. 4, pp. 257-262).
Millikan et al. (J. Clin. Oncol. 21 (5): 878-883 (2003)).
Van Belle et al. (Anticancer Res. 13: 2389-2392 (1993)).
Van Ginckel et al. (Eur. J. Cancer Clin. Oncol. vol. 20 (1): 99-105 (1984)).
Terauchi et al. (Int. J. Clin. Oncol. (2002) 7:356-360).
Okawa et al. (Breast Cancer (2004) 11 (3):309-312).
Van Veldhuizen et al. (Cancer 2003, vol. 98 (9); p. 1855-1862).
Chong et al. (ACS Chemical Biology. (2007), 2 (4); p. 263-270).
Chou et al. (Food and Chemical Toxicology. 45 (2007) 1356-1367.
Song, et al., “Over-Expression of Heme Oxygenase-1 Promotes Oxidative Mitochondrial Damage in Rat Astroglia”, 2006, Journal of Cellular Physiology, v. 206, p. 655-663.
Vlahakis, et al., “Anti-Plasmodium Activity of Imidazole-Dioxolane Compounds”, 2006, Bioorganic and Medicinal Chemistry Letters, v. 16, p. 2396-2406.
Roman, et al., “Heme Oxygenase Inhibition by 2-Oxy-Substituted 1-(1H-Imidazol-1-yl)-4-Phenylbutanes: Effect of Halogen Substitution in the Phenyl Ring”, 2007, Bioorganic and Medicinal Chemistry Letters, v. 15, p. 3225-3234.
Kinobe, et al., “Selectivity of Imidazole-Dioxolane Compounds for In Vitro Inhibition of Microsomal Haem Oxygenase Isoforms”, 2006, British Journal of Pharmacology, v. 147, p. 307-315.
Vlahakis, et al., “Synthesis and Evaluation of Azalanstat Analogues as Heme Oxygenase Inhibitors”, 2005, Bioorganic and Medicinal Chemistry Letters, v. 15, p. 1457-1461.
Vlahkis, et al., “Imidazole-Dioxolane Compounds as Isozyme-Selective Heme Oxygenase Inhibitors”, 2006, Journal of Medicinal Chemistry, v. 49, No. 14, p. 4437-4441.
Chong, et al., “Inhibition of Angiogenesis by the Antifungal Drug Itraconazole”, 2007, ACS Chemical Biology, v. 2, No. 4, p. 263-270.
Sugishima, et al., “X-Ray Crystallographic and Biochemical Characterization of the Inhibitory Action of an Imidazole-Dioxolane Compound on Heme Oxygenase”, 2007, Biochemistry, v. 46, p. 1860-1867.
Kinobe, et al., “Effectiveness of Novel Imidazole-Dioxolane Heme Oxygenase Inhibitors in Renal Proximal Tubule Epithelial Cells”, 2007, The Journal of Pharmacology and Experimental Therapeutics, v. 323, No. 3, p. 763-770.
Ebert, et al., “Quantitative Structure Activity Relationships of Fungicidally Active Triazoles: Analogs and Stereoisomers of Propiconazole and Etaconazole”, 1989, Z. Naturforsch, v. 44, p. 85-96.
Marinissen, et al., “Inhibition of Heme Oxygenase1- Interferes with Transforming Activity of the Kaposi Sarcoma Herpesvirus-encoded G Protein-coupled Receptor”, 2006, The Journal of Biological Chemistry, v. 281, No. 16, p. 11332-11346.
CAS Registry (online), STN International, Columbus, OH, Registry Nos. 64310-41-4 and 76894-56-9 (2 compounds) 1977 and 1981.
Alaoui-Jamali Moulay
Gupta Ajay
Nakatsu Kanji
Schipper Hyman M.
Szarek Walter A.
Lowenstein & Sandler PC
Osta Biotechnologies
Queen's University at Kingston
Rodriguez-Garcia Valerie
Saeed Kamal A
LandOfFree
Methods of treating cancer with imidazolyl compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating cancer with imidazolyl compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating cancer with imidazolyl compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2681169